

## Detection methods of circulating tumor cells

Klaus Pantel<sup>1</sup>, Catherine Alix-Panabières<sup>2,3,4</sup>

<sup>1</sup>Department of Tumour Biology, Centre of Experimental Medicine, University Cancer Center Hamburg, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; <sup>2</sup>University Medical Centre, University Montpellier I, Saint-Eloi Hospital, Institute of Research in Biotherapy, Laboratory of Rare Human Circulating Cells, Montpellier, France; <sup>3</sup>University Medical Centre, Laboratory of Cell and Hormonal Biology, Arnaud de Villeneuve Hospital, Montpellier, France; <sup>4</sup>University Institute of Clinical Research UMI -EA2415-Epidemiology, Biostatistics & Public Health, France

### KEY WORDS

Epithelial tumor; tumor dissemination; circulating tumor cells; biomarker; personalized medicine

*J Thorac Dis 2012;4(5):446-447. DOI: 10.3978/j.issn.2072-1439.2012.08.15*

Early during the formation and growth of a primary epithelial tumor, cells disseminate through the bloodstream to distant organs. These circulating tumor cells (CTCs) can be enriched and detected via different technologies and CTC analyses are considered as a *real-time "liquid biopsy"* in cancer patients. This biopsy allows the characterization of specific sub-populations of CTCs and may revolutionize cancer detection and management. This editorial highlights the current strategies used for enrichment and detection of CTCs.

CTC detection holds great promise, and many exciting technologies have been developed over the past years. However, detecting CTCs remains technically very challenging. As CTCs occur at very low concentrations (1 CTC in the background of millions of normal hematopoietic cells), their identification and characterization require extremely sensitive and specific analytical methods, which are usually a combination of enrichment and detection procedures (1).

CTC enrichment includes a large panel of technologies based on the different properties of CTCs that distinguish them from the surrounding normal blood cells, including *physical properties* (size, density, electric charges, deformability) and *biological properties* (surface protein expression, mostly EpCAM expression). To increase the yield of CTCs, new technologies based on the combination of different CTC properties have been even developed. After enrichment, the CTC fraction usually still contains a substantial number of leukocytes, and CTCs need to be, therefore, identified

by a method that can distinguish tumor cells from normal blood cells at the single cell level. Among the *protein-based strategies*, the CellSearch® system (FDA-USA cleared) and many other CTC assays use the same identification step: cells are fluorescently stained for cytokeratins (CK; positive marker), the common leukocyte antigen CD45 (negative marker), and a nuclear dye (DAPI); CTCs are identified as CK<sup>+</sup>/CD45<sup>-</sup>/DAPI<sup>+</sup> cells. One key question is whether the detected CTCs are viable or apoptotic because only functional cells should be able to contribute to metastasis formation. In order to detect only living CTCs, the functional EPISPOT assay (for EPithelial ImmunoSPOT), which can be added to any kind of enrichment step, was introduced for CTC detection. Avoiding direct contact with the target cells, this technique assesses the presence of CTCs based on secreted, shed, or released proteins during 48 h of short-term culture (2-4). These last 4 years, there was an important focus on the development of microfluidic devices ("CTC-chips"), which can handle very small blood volumes. The first CTC-chip consisted of an array of anti-EpCAM antibody-coated microposts and has been further developed into a herringbone structure (5). Since 2008, new CTC-chips have been improved [i.e., Ephesia-chip (6), chip-based micro-Hall detector (7), CTC-chip for CK<sup>+</sup> & CK<sup>-</sup> CTCs (8)]. Moreover, among *mRNA-based strategies*, assays targeting specific mRNAs are the most widely used alternative to immunological assays to identify CTCs. In breast cancer, the CK19 mRNA has been most frequently used in clinical studies (9). Many transcripts (e.g., encoding CK18, CK19, CK20, MUC1, PSA, and CEA), however, are also expressed at low levels in normal blood and BM cells (9-10), and quantitative RT-PCR assays with validated cut-off values are therefore required to overcome this problem. Moreover, gene transcription might be modified in CTCs, which argues in favour of multimarker RT-PCR approaches. Recently, Markou *et al.* described a new liquid-bead-array hybridization assay (11).

In the CTC field, a very important biological question remains to be elucidated: the epithelial-to-mesenchymal transition (EMT).

Corresponding to: Catherine Alix-Panabières. Laboratory of Rare Human Circulating Cells, Montpellier, France, 80 avenue Augustin Fliche, 34295 Montpellier France. Email: c-panabieres@chu-montpellier.fr.

Submitted Jul 20, 2012. Accepted for publication Aug 23, 2012.  
Available at [www.jthoracdis.com](http://www.jthoracdis.com)

ISSN: 2072-1439

© Pioneer Bioscience Publishing Company. All rights reserved.

EMT is a complex process leading to cell dedifferentiation and increased motility via rearrangements of cellular contact junctions and eventually loss of cell adhesion. During this transition cells switch partially or fully their epithelial phenotype (i.e., expression of EpCAM, E-Cadherin, and CK) into a mesenchymal one (i.e., expression of N-Cadherin and Vimentin) and this switch has still an unknown impact on technologies identifying CTCs. However, as EMT might particularly affect tumor cells with stem cell-like properties (12), current assays based on epithelial antigens may miss the most aggressive CTC subpopulation (13). Thus, there is an urgent need for optimizing CTC detection methods through the inclusion of markers that are not repressed during EMT but still allow the analysis to distinguish CTCs from the surrounding blood cells.

Besides the choice of the appropriate CTC marker, the limited blood sample volumes available from cancer patients may impose a serious limitation on the detection of rare events such as CTCs, mostly in localized cancer with no overt distant metastases where the CTC counts are very low. Thus, technologies allowing the analysis of high blood volumes are of real interest and still deserve great attention. An elegant way to overpass this limitation is to target the CTCs directly *in vivo* via the Gilupi nanodetector®. During a 30 min application of this device in the peripheral arm vein, up to 1.5 L of blood, including the CTCs, pass the 2 cm functionalized area of the nanodetector and enable a high number of CTCs to be bound by the anti-EpCAM antibodies (14). An alternative approach is the development of leukapheresis, elutriation for subsequent *ex vivo* CTC analyses using flow cytometry and real-time PCR for molecular characterization (15).

Detection and molecular characterization of CTCs is one of the most active areas of translational cancer research with 427 clinical studies including CTCs as a potential new independent biomarker: CTCs reflect cancer progression in real-time and this information may be in particular helpful in the context of systemic therapies. The specificity and clinical utility of these CTC detection methods have to be demonstrated in large prospective multicenter studies to reach the high level of evidence required for introduction into clinical practice. In the future, CTC characterization will contribute to guide specific targeted therapies applied to a defined population of cancer patients at a certain therapeutic window, which is the hallmark of personalized medicine.

### Acknowledgements

**Disclosure:** K. Pantel: speaker honoraria (Roche, Novartis, Merck, Bayer, Siemens), advisory board (Veridex) and research support

(Veridex, Roche, Novartis).

C. Alix-Panabières: speaker honoraria (Sanofi, Roche), advisory board (Veridex) and research support (Veridex, Roche).

### References

1. Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. *Annu Rev Med* 2012;63:199-215.
2. Alix-Panabières C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. *Recent Results Cancer Res* 2012;195:69-76.
3. Alix-Panabières C, Vendrell JP, Slijper M, et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. *Breast Cancer Res* 2009;11:R39.
4. Alix-Panabières C, Vendrell JP, Pellé O, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. *Clin Chem* 2007;53:537-9.
5. Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. *Proc Natl Acad Sci USA* 2010;107:18392-7.
6. Saliba AE, Saia L, Psychari E, et al. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. *Proc Natl Acad Sci USA* 2010;107:14524-9.
7. Issadore D, Chung J, Shao H, et al. Ultrasensitive Clinical Enumeration of Rare Cells *ex Vivo* Using a Micro-Hall Detector. *Sci Transl Med* 2012;4:141ra92.
8. Pecot CV, Bischoff FZ, Mayer JA, et al. A novel platform for detection of CK+ and CK- CTCs. *Cancer Discov* 2011;1:580-6.
9. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. *Nat Rev Cancer* 2008;8:329-40.
10. Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. *Clin Chem* 2011;57:1242-55.
11. Markou A, Strati A, Malamou N, et al. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. *Clin Chem* 2011;57:421-30.
12. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008;133:704-15.
13. Bednarz-Knoll N, Alix-Panabières C, Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. *Cancer Metastasis Rev* 2012. [Epub ahead of print].
14. Saucedo-Zeni N, Mewes S, Niestroj R, et al. A novel method for the *in vivo* isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. *Int J Oncol* 2012. [Epub ahead of print].
15. Eifler RL, Lind J, Falkenhagen D, et al. Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. *Cytometry B Clin Cytom* 2011;80:100-11.



**Cite this article as:** Pantel K, Alix-Panabières C. Detection methods of circulating tumor cells. *J Thorac Dis* 2012;4(5):446-447. DOI: 10.3978/j.issn.2072-1439.2012.08.15